Navigation Links
HeartWare International, Inc. Closes US$60 Million Financing
Date:8/17/2009

FRAMINGHAM, Mass., and SYDNEY, Aug. 17 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) announced today the completion of its offering of approximately 2.7 million shares of its common stock in a private placement in the United States and Australia (the "Offerings"). Investors in the Offerings purchased the shares at a purchase price of US$22.00 per share resulting in gross proceeds of approximately US$60 million to HeartWare, before deducting the placement agent's fee and estimated offering expenses.

The issuance of approximately 1.39 million of the total number of shares that investors have committed to purchase in the Offerings is subject to approval of HeartWare's stockholders in accordance with Australian Securities Exchange Listing Rules and Nasdaq Stock Market Rules and, as a result, approximately US$30.5 million of the proceeds Offerings will be held in escrow and will be released if and when stockholder approval is obtained. The meeting of the stockholders will be scheduled for a date prior to December 15, 2009.

The securities described herein have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and unless so registered may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of our securities in any jurisdiction.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), to treat patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, the only full-output pump designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has commercial approval to sell its HVAD(TM) pump in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

    For further information:

                                                  US Investor Relations
        Howard Leibman                            Matt Clawson
        HeartWare International, Inc.             Allen & Caron Inc
        Email. howard.leibman@heartware.com.au    Email. matt@allencaron.com
        Tel. +61 2 9238 2064                      Tel. +1 949 474 4300

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the progress of clinical trials. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in "Item 1A. Risk Factors" in our Annual Report on Form 10-K filed with the SEC, and those described in other reports filed from time to time with the SEC.


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HeartWare to Present at Canaccord Adams 29th Annual Global Growth Conference
2. HeartWare International, Inc. Announces US$55 Million Financing
3. Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction
4. HeartWare to Webcast Annual Meeting
5. HeartWare to Present at Eighth Annual JMP Securities Research Conference
6. Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission
7. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
8. HeartWare to Present at Seventh Annual JMP Securities Research Conference
9. HeartWare Receives Conditional Approval of IDE
10. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
11. HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: